Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostriatal dopamine release in vivo.
The interactions of phencyclidine (PCP) with the mesocortical dopaminergic system were of interest because of the putative role of this pathway in the etiology of schizophrenia. In the present investigation we examined the effects of PCP, and PCP-receptor agonist, ketamine, on dopamine (DA) release by measuring the levels of 3-methoxytyramine (3-MT), the only DA metabolite which is a reliable indicator of DA release in vivo. PCP increased DA release in the amygdala, pyriform and prefrontal cortices, while ketamine was less potent than PCP in this respect. In contrast to the changes in DA release in the cortical regions, ketamine decreased DA release in striatum, while PCP did not change DA release.
Rao
T S
TS
CNS Diseases Research, G. D. Searle & Co., c/o Monsanto Co., St. Louis, Mo 63198.
Kim
H S
HS
Lehmann
J
J
Martin
L L
LL
Wood
P L
PL
D000679:Amygdala / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D005625:Frontal Lobe / Q000187:drug effects* / Q000378:metabolism; D007649:Ketamine / Q000494:pharmacology*; D008297:Male; D010622:Phencyclidine / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D007649:Ketamine; D010622:Phencyclidine; D004298:Dopamine